EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies

Ryo Honda iD

Cancer Science · 06.08.2026

DOI: 10.1111/cas.70497 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 06.08.2026. Verfasst von Ryo Honda. Beteiligte Einrichtung: United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins. In the randomized phase III RASolute 302 trial, daraxonrasib substantially improved survival over chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma while maintaining manageable toxicity, thereby establishing a clinically useful therapeutic window for pan‐RAS inhibition. Nevertheless, epithelial toxicity and acquired resistance, including mutations affecting ternary‐complex formation and mechanisms associated with increased KRAS abundance, remain important challenges. This review discusses the mechanistic and clinical development of daraxonrasib and examines emerging strategies designed to improve the depth, durability, and selectivity of RAS suppression. These include pan‐KRAS inhibitors, targeted RAS degraders, RAS‐cleaving protein biologics, and tumor‐directed delivery systems. Together, these approaches may reshape the treatment of RAS‐driven cancers across tumor types and disease stages.

Schlagwörter

Stichwörter der Autor:innen

DaraxonrasibRAS proteinsdrug resistancemolecular targeted therapyneoplasmpan‐RAS inhibition

Autor:innen und Institutionen

  • United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
  • Center for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Japan.

ORCID-Profile: Ryo Honda

Zitieren

APA

Honda, R. (2026). Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies. Cancer Science. https://doi.org/10.1111/cas.70497

Vancouver

Honda R. Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies. Cancer Science. 2026. doi:10.1111/cas.70497

BibTeX
@article{Honda2026,
  author = {Honda, Ryo},
  title = {Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70497}
}
Kostenlos starten →